Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease Skip to content The CRC Digest Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease A prospective study of 1,000 stage II-III CRC patients found that distinct perioperative immunocircadian recovery trajectories were associated with postoperative ctDNA-based minimal residual disease and long-term survival outcomes. (Surgery) This content is informational
Biological Age and Neighborhood Deprivation Linked to Psychological Distress During Chemotherapy Skip to content The CRC Digest ♥ LIVING WITH CRC Biological Age and Neighborhood Deprivation Linked to Psychological Distress During Chemotherapy An analysis of 958 adults with stage II-III CRC receiving chemotherapy found that biological age and neighborhood deprivation predict depression and anxiety symptoms, highlighting biosocial factors that may influence mental
Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) serves as a biomarker for recurrence after curative resection of colorectal cancer liver metastases, potentially guiding post-surgical surveillance strategies. (Clinical Colorectal Cancer) This
KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth A study in KRAS-mutant CRC patients and mice found that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens, which predicts poor prognosis and promotes malignant phenotypes in KRAS-mutant tumors. (Cell Host & Microbe) This
Multigene Panel Testing Yield Quantified in Colorectal Cancer Patients Skip to content The CRC Digest ◇ RESEARCH Multigene Panel Testing Yield Quantified in Colorectal Cancer Patients A systematic review and meta-analysis examined the diagnostic yield of germline multigene panel testing using next-generation sequencing in unselected patients with colorectal cancer, helping clarify how often inherited genetic factors contribute to diagnosis. (Lancet
AI Tool Shows Promise for Scalable Colorectal Cancer Screening Skip to content The CRC Digest ▪ SCREENING AI Tool Shows Promise for Scalable Colorectal Cancer Screening Researchers describe progress toward practical artificial intelligence applications that could expand access to colorectal cancer screening at scale. (Annals of Oncology) This content is informational only and does not constitute medical advice. Always consult
Developing Quality Programs to Track Colorectal Cancer Screening Skip to content The CRC Digest Developing Quality Programs to Track Colorectal Cancer Screening A new article proposes features for an ideal tracking system to enhance screening program performance, noting that common issues include suboptimal return rates for stool-based tests, lack of timely colonoscopy after abnormal results, and surveillance recommendations
Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids Skip to content The CRC Digest Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids Researchers used paired patient-derived normal and tumor colorectal organoids to investigate how calcitriol (the active vitamin D metabolite) modulates chemotherapy response. Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil and
Study Examines Attachment Style, Symptom Distress, and Depression in CRC Survivors Skip to content The CRC Digest ♥ LIVING WITH CRC Study Examines Attachment Style, Symptom Distress, and Depression in CRC Survivors A cross-sectional study of 90 colorectal cancer survivors who completed treatment within the past three months explored relationships among adult attachment styles, symptom distress, and depressive symptoms, and whether mindfulness
Review Outlines Advances and Challenges to Colonoscopy Quality Skip to content The CRC Digest ▪ SCREENING Review Outlines Advances and Challenges to Colonoscopy Quality A new article in Gastrointestinal Endoscopy Clinics of North America outlines current advances, challenges, and best practices for high-quality colonoscopy, noting that colorectal cancer remains the third most common cancer by incidence and second most
Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC Skip to content The CRC Digest ◇ RESEARCH Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.
Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC Skip to content The CRC Digest ▸ TREATMENT Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC A phase Ib/II trial evaluated the chemotherapy-free combination of ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in previously treated KRAS G12C–mutated metastatic colorectal cancer, showing encouraging antitumor
Vietnamese Cohort Compares Early- vs Late-Onset CRC Outcomes Skip to content The CRC Digest Vietnamese Cohort Compares Early- vs Late-Onset CRC Outcomes A retrospective study of 486 patients who underwent curative resection in Vietnam's Mekong Delta compared clinicopathologic features and survival between early-onset and late-onset colorectal cancer. (Arq Bras Cir Dig) This content is informational only
Risk Factors for Early-Onset CRC Reviewed Skip to content The CRC Digest Risk Factors for Early-Onset CRC Reviewed A clinical review highlights that early-onset CRC (diagnosed before age 50) arises from both nonmodifiable factors (age, family history, race/ethnicity) and modifiable factors (obesity, diet, inactivity, alcohol, tobacco). (Gastrointest Endosc Clin N Am) This content is informational
Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC Skip to content The CRC Digest ◇ RESEARCH Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC Researchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials) This content is informational only
Meta-Analysis Examines Fecal Immunochemical Test Accuracy Skip to content The CRC Digest ▪ SCREENING Meta-Analysis Examines Fecal Immunochemical Test Accuracy A systematic review and meta-analysis evaluated the diagnostic accuracy of quantitative fecal immunochemical tests (FIT) for colorectal cancer and advanced neoplasm, examining variations in performance by sex, geographic region, study design, FIT platform, and positivity threshold. (Cancer
Blood-Based CRC Screening Tests Show Promise but Have Key Limitations Skip to content The CRC Digest ▪ SCREENING Blood-Based CRC Screening Tests Show Promise but Have Key Limitations Three blood-based CRC screening tests (Epi proColon, Shield, and the Freenome test) have completed large validation studies, but all show low sensitivity for advanced precancerous lesions, low rates of follow-up colonoscopy after an
Early-Onset Colorectal Cancer Incidence Accelerates Through 2023 Skip to content The CRC Digest ▪ SCREENING Early-Onset Colorectal Cancer Incidence Accelerates Through 2023 SEER data show early-onset CRC incidence accelerated during 2019-2023 with an annual percent change of 8.3%, while incidence among adults 65 and older declined. Black patients more often presented with stage IV disease (33.9%